Grand Angels

Grand Angels was founded by former Grand Bank founder and CEO Charles C. Stoddard and serial entrepreneur, Craig T. Hall. The firm is the only regional investment group that offers mentoring paired with a relatively patient exit strategy, meaning invested funds may not need to be returned as quickly as would be expected by commercial or other investors. Grand Angels typically invests from $250K to $1M in early-stage companies across a wide range of sectors. Grand Angels invests in businesses located in Michigan, with a preference for those located in Kent, Ottawa and Muskegon counties. Grand Angels has invested over $8 million since its inception.

Robert Lynn Herr

Director

Michael Jandernoa

Co-Founder & Board Member

28 past transactions

Akadeum Life Sciences

Series B in 2021
Akadeum Life Sciences is working on the problem of isolating mammalian and bacterial cells from complex mixtures. It creates the simplest bioseparation products and fundamentally change the way that isolating cells and other biological targets approached. The company currently uses microbubbles for applications in cell separation and other related areas. Akadeum Life Sciences was founded in 2014 and is headquartered in Ann Arbor, Michigan, United States.

Tetra Therapeutics

Series A in 2016
Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders.

ONL Therapeutics

Private Placement in 2020
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptor cell.

Blue Medora

Series A in 2015
Blue Medora is pioneering total IT system insight without plugins. Its software easily connects system health and performance data--no matter its source--with the world’s leading monitoring and analytics platforms, breaking barriers to today’s IT challenges. Based in Grand Rapids, Mich, Blue Medora helps more than 350 customers to unlock Dimensional Data across their IT stack.

Accuri Cytometers

Series A in 2005
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

AzulStar

Venture Round in 2011
AzulStar, Inc. provides 4G/5G wireless broadband Internet and communications services to commercial, government, and multi-tenant unit customers. The company offers high-speed Internet access, managed wireless networking, and intelligent transportation; and residential wireless fiber, business wireless fiber, and other services. It operates carrier-class networks in Michigan and New Mexico. AzulStar, Inc. was formerly known as Ottawa Wireless, Inc. The company was founded in 2003 and is based in Ada, Michigan.

Janeeva

Venture Round in 2007
Janeeva provides the most comprehensive set of software to both users and providers of outsourcing services for Outsourcing Relationship Management (ORM). The Janeeva Assurance family of products provides a one-stop shop for governance activities of outsourced operations. With Janeeva Assurance, governance groups, providers and internal customers know exactly where to go to arrange for additional resources, raise or manage an issue, track SLAs, or compare performance across multiple providers. The transparency that can be achieved with Janeeva Assurance and the institutional memory it creates, increases efficiency of interactions, promotes trust and minimizes missed opportunities. And the wealth of data collected by Janeeva Assurance can be mined to identify trends, process bottlenecks and best practices.

Tetra Discovery

Series A in 2016
Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system. Their research focuses on developing new treatments for depression and schizophrenia. Severe forms of depression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability.

ONL Therapeutics

Series B in 2020
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptor cell.

VNN

Series A in 2014
VNN is the largest and fastest growing high school sports marketing platform in America. As the exclusive web/mobile platform for over 7million passionate fans across 40+ states (adding 8,000 fans daily), VNN is rapidly aggregating the fragmented, multi-billion dollar high school sports market onto an intelligent platform that transforms the consumer experience of high school sports.

Reconstruct

Seed Round in 2016
Reconstruct’s platform provides a ‘virtual command center’ of project replicas that enables project executives to more proactively and precisely manage construction progress including detecting current, past, and future performance issues. The platform’s 3D timelines enable near real-time coordination among general contractors, subs, owners, and lenders.

Ripple Science

Seed Round in 2020
Ripple Science Corporation develops a web-based software for health sciences that facilitates the recruitment and management of participants in clinical, translational, and social science studies. The company’s software is used for study dashboard, recruitment campaign management, potential participant tracking, enrolled participant tracking, and task management. It offers solutions for academic investigators, clinical trial sites, and CROs. Ripple Science Corporation was founded in 2016 and is based in is based in Ann Arbor, Michigan.

Micro-LAM, Inc.

Angel Round in 2017
Micro-LAM Technologies offers cutting edge technology through its state-of-the-art retrofittable system that is set to be a game-changer in the advanced manufacturing industry. The hybrid laser-diamond cutting tool system provides profitable solutions for machining hard and brittle materials. It was established in 2012 and is based in Portage, Michigan.

Tetra Discovery

Seed Round in 2015
Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system. Their research focuses on developing new treatments for depression and schizophrenia. Severe forms of depression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability.

Blue Medora

Seed Round in 2013
Blue Medora is pioneering total IT system insight without plugins. Its software easily connects system health and performance data--no matter its source--with the world’s leading monitoring and analytics platforms, breaking barriers to today’s IT challenges. Based in Grand Rapids, Mich, Blue Medora helps more than 350 customers to unlock Dimensional Data across their IT stack.

Blue Medora

Series B in 2016
Blue Medora is pioneering total IT system insight without plugins. Its software easily connects system health and performance data--no matter its source--with the world’s leading monitoring and analytics platforms, breaking barriers to today’s IT challenges. Based in Grand Rapids, Mich, Blue Medora helps more than 350 customers to unlock Dimensional Data across their IT stack.

HistoSonics

Series B in 2017
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Ocuphire Pharma

Seed Round in 2019
Ocuphire Pharma is a clinical-stage biopharmaceutical company committed to the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. We are currently focused on providing a novel once-daily eye drop treatment option, Nyxol®, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of our strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes, and to seek strategic partners for global commercialization.

Tetra Discovery

Seed Round in 2011
Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system. Their research focuses on developing new treatments for depression and schizophrenia. Severe forms of depression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability.

Ocuphire Pharma

Private Placement in 2019
Ocuphire Pharma is a clinical-stage biopharmaceutical company committed to the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. We are currently focused on providing a novel once-daily eye drop treatment option, Nyxol®, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of our strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes, and to seek strategic partners for global commercialization.

Ambiq Micro

Venture Round in 2018
Ambiq Micro is an early-stage fabless semiconductor company that is developing ultra-low-power mixed-signal solutions for a new generation of wireless electronics. Ambiq Micro was founded in 2010 on the simple yet powerful notion that extremely low power semiconductors are the key to the future of electronics. Through the use of their pioneering ultra-low-power technology, they help innovative companies around the world develop differentiated solutions that reduce or eliminate the need for batteries, lower overall system power, and maximize industrial design flexibility.

Tetra Discovery

Seed Round in 2013
Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system. Their research focuses on developing new treatments for depression and schizophrenia. Severe forms of depression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability.

HistoSonics

Debt Financing in 2015
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

KitoTech Medical

Convertible Note in 2020
KitoTech Medical, Inc. develops microMend, which is a medical product for closing wounds, including lacerations and surgical incisions. KitoTech Medical, Inc. was formerly known as Marco Pharmaceuticals, Inc. The company was founded in 2011 and is based in Seattle, Washington.

TransCorp Spine

Series A in 2011
TransCorp Spine manufactures medical devices and procedures to restore spinal function and preserve healthy tissue. Its product includes SpinePort, a MIS access system. David Lowry, Des O'Farrell, and Scott Tuinstra founded TransCorp Spine in 2008. It has its headquarters in Byron Center in Michigan.

Gemphire Therapeutics

Debt Financing in 2016
Gemphire Therapeutics manufactures and markets Gemcabene, an LDL cholesterol-lowering medication. It is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The company was founded in 2014 and is based in Northville, Michigan.

Ripple Science

Seed Round in 2020
Ripple Science Corporation develops a web-based software for health sciences that facilitates the recruitment and management of participants in clinical, translational, and social science studies. The company’s software is used for study dashboard, recruitment campaign management, potential participant tracking, enrolled participant tracking, and task management. It offers solutions for academic investigators, clinical trial sites, and CROs. Ripple Science Corporation was founded in 2016 and is based in is based in Ann Arbor, Michigan.